What is Equillium?
Equillium operates at the intersection of advanced immunology and therapeutic innovation. The company specializes in the development of novel treatments for immuno-inflammatory conditions, a sector characterized by high barriers to entry and significant clinical complexity. By focusing on diseases where current standard-of-care options are insufficient, Equillium occupies a vital niche in the biotechnology ecosystem. Its research-driven approach aims to translate complex biological insights into actionable clinical outcomes, thereby enhancing the quality of life for patients suffering from chronic and debilitating autoimmune pathologies.
How much funding has Equillium raised?
Equillium has raised a total of $100M across 3 funding rounds:
Share Placement
$15M
Stock/Share Issuance
$50M
Stock/Share Issuance
$35M
Share Placement (2020): $15M with participation from Lincoln Park Capital Fund , LLC
Stock/Share Issuance (2025): $50M led by Adage Capital Management, Janus Henderson Investors, and Woodline Partners
Stock/Share Issuance (2026): $35M supported by RA Capital Management
Key Investors in Equillium
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
Adage Capital Management
Adage Capital Management is a money management firm primarily focused on S&P 500 assets, headquartered in Boston, Massachusetts.
Janus Henderson Investors
Janus Henderson is a global investment management firm that provides a broad range of investment solutions and advisory services to institutional investors, financial professionals, and individual clients.
What's next for Equillium?
With the recent influx of capital, Equillium is expected to prioritize the advancement of its lead therapeutic candidates through pivotal clinical trials. The strategic focus will likely shift toward scaling manufacturing capabilities and expanding regulatory engagement to facilitate potential commercialization pathways. As the company navigates the complexities of late-stage clinical development, the continued support from its institutional partners will be instrumental in mitigating operational risks and ensuring the successful execution of its long-term research objectives. The firm remains committed to its mission of delivering transformative therapies, leveraging its strengthened balance sheet to maintain a competitive edge in the rapidly evolving biotech market.
See full Equillium company page
